Neurotransmitter targeting in the treatment of depression.
about
The noradrenergic paradox: implications in the management of depression and anxietySimvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice.Brain serotonin signaling does not determine sexual preference in male mice.Major depressive disorder: mechanism-based prescribing for personalized medicineAdynamic ileus and diarrhoea: a rare adverse effect of antidepressants.In vivo investigation of escitalopram's allosteric site on the serotonin transporterRelationship Between Serum Vitamin D Levels and Symptoms of Depression in Stroke PatientsSympathoneural and adrenomedullary responses to mental stressChronic caffeine treatment enhances the resilience to social defeat stress in mice.Neuroanatomic pathways associated with monoaminergic dysregulation after stroke.The relationship between the presence of depressive symptoms and the severity of self-reported knee pain in the middle aged and elderly.Effects of methylphenidate during emotional processing in amphetamine users: preliminary findings.Adjunctive brexpiprazole for the treatment of major depressive disorder.Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants.Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5.Criticisms of drugs in early development for the treatment of depression: what can be improved?Tyrosine hydroxylase down-regulation after loss of Abelson helper integration site 1 (AHI1) promotes depression via the circadian clock pathway in mice.
P2860
Q26752868-14213B03-3319-47AF-9CC7-B6891588D7E8Q33725859-DDF3F196-6E08-4D7A-85C6-AAB66D6A31C7Q35113173-800920A2-585D-4EC9-90D9-096C56B28532Q35284412-78AFFE43-C700-4CE3-A358-6A82D37CA707Q35691706-4CC8CCBD-8817-4CC2-80F4-EDDBFDB9F170Q36494042-0FFA9B19-1172-4BBB-942E-B262B069ACB8Q36643920-5D35D1EE-43C2-4E65-89E6-4FACDB58C04DQ37614066-8212C724-389C-42E2-814F-5BE7F5A036ABQ39271600-96DAB8D3-8E7F-4B02-A9B3-4FC1D1B86BF7Q39717355-4E5E9379-3E3F-4CB9-970B-FB64B74FADDEQ40930838-AFA1AD25-66E7-43BF-A2A2-CCBBDFBD4CE4Q47763367-AC760618-274F-4464-A169-AAC0874716E8Q48037953-E2268EF7-D73B-4A55-857F-8F8A0CAD62C5Q48046839-2A0C2EA2-B0AB-4BBD-A1AF-12450CA3A7B7Q48077200-D4FA4D61-5551-4E97-A6D7-B56DD63AC46FQ48148268-62BD0F68-2DD8-486E-AF06-773FB9EDB43FQ49960381-60432AD4-53A8-46D4-8FAC-37BCE0931B88
P2860
Neurotransmitter targeting in the treatment of depression.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neurotransmitter targeting in the treatment of depression.
@en
type
label
Neurotransmitter targeting in the treatment of depression.
@en
prefLabel
Neurotransmitter targeting in the treatment of depression.
@en
P356
P1476
Neurotransmitter targeting in the treatment of depression.
@en
P2093
Pierre Blier
P356
10.4088/JCP.12084SU1C.04
P478
74 Suppl 2
P577
2013-01-01T00:00:00Z